Aurora Kinase Inhibitors Market Trends and Opportunities for the Industry by 2023

The Aurora kinases are enzymes which are crucial for cell proliferation. These enzymes are responsible for dividing genetic material of the parent cell during the process of mitosis by controlling chromatid segregation. The defect related to this process is largely associated with cancer genesis in human body. In this way active involvement of aurora kinase enzymes in initiating cancer genesis has lead considerable attention of therapists to their inhibition in the work towards cancer treatment. There are three kind of aurora kinase found in human body namely A, B and C. Aurora C is mainly restricted to the process of spermatogenesis while remaining two are responsible various tumerogenesis. Though these are not restricted to particular cancer type but there are some examples of cancer in which over expression of specific aurora kinases has been observed. Amplified aurora A in lung, pancreatic, colon, cervical, prostrate, ovarian, brain and breast whereas aurora B in breast, colon, thyroid, oral and non small cell lung.

This Report Gives Readers a Comprehensive Overview of Aurora Kinase Inhibitors Market: http://www.transparencymarketresearch.com/aurora-kinase-inhibitors-market.html

Cancer is considered to the major causative factor for mortality worldwide with increasing incidence and prevalence day by day. All regions of the world have seen continuous rise in number of cancer patients in past decade. WHO predicted that annual cancer cases will reach to 19.3 million by 2025 from the 14.1 million annually in year 2012, whereas annual cases in 2008 were 12.7 million of which 1.7 million were women newly diagnosed with breast cancer that accounted for 20% in 2008. WHO mentions that cancer kills 8.2 millions globally out of which 522,000 woman from breast cancer. It is mentionable that incidence rate is still higher in developed region whereas death rates are higher in less developed countries. In all the cancer types, number of patients suffering with head and neck, gastrointestinal, breast and uterine cancer are highest.

Aurora family Kinase Assay/Inhibitor screening kits are designed to estimate the inhibitory effect of individual Aurora activity in the test chemical accurately. Merck Millipore, MBL International, Perkin Elmer, SignalChem are some of the leading companies which manufacture screening kits.

Geographically North American region accounts for the largest market share in this market which is followed by developing Asia Pacific market and European market. The market for Aurora Kinase inhibitor is driven by continuous increasing number of cancer cases and improving healthcare standard outside the developed world and advancements in early diagnosis of cancer. However there are restrictions such as high cost involved in drug development, lower spending capacity of poorer countries and need of real time clinical data. There are different kind of biological therapies in oncology such as Tyrosine kinase inhibitor (includes erlotinib, imatinib, gefitinib, dasatinib, sunitinib, ruxolitinib, etc.), monoclonal antibodies (includes trastuzumab, bevacizumab and cetuximab, etc.) whereas some are in development stage such as Aurora Kinase Inhibitor (Hesperadine, VX-680). Currently there is no molecule is approved in this market however there are almost 30 molecules of Aurora Kinase inhibitor class in development stage at different levels. With increase in cancer patients the market for Aurora Kinase Inhibitor market is set to increase.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Aurora Kinase Inhibitors Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4679

Some of the major players in Aurora Kinase Inhibitor development market are Merck, Pfizer, Amgen, Millennium Pharmaceuticals, Cyclacel Pharmaceuticals, Bristol Myers Squibb. Along with these, there are companies such as Roche, Novartis, Eli Lilly, AstraZeneca, Celgene, Sanofi and GlaxoSmithKline have made their mark in oncology.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.